Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
This study has been completed.
Study NCT00002240 Information provided by Bristol-Myers Squibb
First Received on November 2, 1999. Last Updated on April 28, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Atazanavir
Nelfinavir mesylate
Stavudine
Didanosine
Additional drug interventions recognized in this trial
Anti-HIV Agents
HIV Protease Inhibitors
Nelfinavir
Protease Inhibitors
Reverse Transcriptase Inhibitors
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Retroviral Agents
Antimetabolites
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Bristol-Myers Squibb
Back to top of Main Content
